Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-cyclopropyl-N-(trans-4-pyridin-3-ylcyclohexyl)-4-[(1S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]benzamide
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
This compound is a synthetic small molecule belonging to the benzamides class. It features a trifluoromethyl and hydroxy group on the benzene ring and a cyclopropane-substituted trans-pyridin-cyclohexane moiety. It is an experimental drug with no approved indications or clinical trials reported. The primary known molecular target is the enzyme 11β-hydroxysteroid dehydrogenase type 1 (HSD11B1), which plays a role in glucocorticoid metabolism[7][3]. Inhibition of HSD11B1 has been investigated as a potential therapeutic strategy for metabolic disorders such as obesity and type 2 diabetes.
- Other names
- N-cyclopropyl-N-[trans-4-(3-pyridinyl)cyclohexyl]-4-[(2S)-1,1,1-trifluoro-2-hydroxypropan-2-yl]benzamideN-cyclopropyl-N-(trans 4 pyridin 3 yl cyclohexyl) 4 (1S) 222 trifluoro 1 hydroxy 1 methylethyl benzamide
02
Targets
HSD11B1 (11-beta-hydroxysteroid dehydrogenase type 1)
Beyond the preview
Go deeper on N-cyclopropyl-N-(trans-4-pyridin-3-ylcyclohexyl)-4-[(1S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]benzamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-cyclopropyl-N-(trans-4-pyridin-3-ylcyclohexyl)-4-[(1S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]benzamide.